Rotarix in developing countries: paving the way for inclusion in national childhood immunization programs in Africa
- PMID: 20684722
- DOI: 10.1086/653547
Rotarix in developing countries: paving the way for inclusion in national childhood immunization programs in Africa
Abstract
Rotavirus gastroenteritis causes more than half a million deaths annually among children aged <5 years, the great majority of which occur in Africa and Asia. Vaccination is considered to be the most effective public health strategy to prevent rotavirus disease and to reduce the significant global burden of rotavirus gastroenteritis. Rotarix (GlaxoSmithKline Biologicals) is an oral, live attenuated rotavirus vaccine derived from a human G1P[8] rotavirus strain. Results of phase III studies in Europe, Latin America, and Asia have shown that Rotarix offers sustained high protection against severe rotavirus gastroenteritis during the first 2 years of life, when disease burden is highest, with broad protection demonstrated against each of the 5 main rotavirus types that circulate globally (G1, G2, G3, G4, and G9). Coupled with the availability of local burden of disease data and promising interim efficacy data from an ongoing study in Malawi and South Africa, this further reinforces the case for introduction of this rotavirus vaccine in national childhood immunization programs in Africa, where rotavirus-related mortality is significant.
Similar articles
-
Update on Rotarix: an oral human rotavirus vaccine.Expert Rev Vaccines. 2009 Dec;8(12):1627-41. doi: 10.1586/erv.09.136. Expert Rev Vaccines. 2009. PMID: 19943758 Review.
-
Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.Vaccine. 2012 Apr 27;30 Suppl 1:A24-9. doi: 10.1016/j.vaccine.2011.08.124. Vaccine. 2012. PMID: 22520132 Clinical Trial.
-
Rotavirus vaccination within the South African Expanded Programme on Immunisation.Vaccine. 2012 Sep 7;30 Suppl 3:C14-20. doi: 10.1016/j.vaccine.2012.04.018. Vaccine. 2012. PMID: 22939015 Review.
-
Rotavirus vaccines: targeting the developing world.J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6. doi: 10.1086/431504. J Infect Dis. 2005. PMID: 16088799
-
Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.J Infect Dis. 2009 Nov 1;200 Suppl 1:S291-9. doi: 10.1086/605059. J Infect Dis. 2009. PMID: 19817612 Review.
Cited by
-
Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United States.J Virol. 2018 Dec 10;93(1):e01476-18. doi: 10.1128/JVI.01476-18. Print 2019 Jan 1. J Virol. 2018. PMID: 30333170 Free PMC article.
-
Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Curr Drug Metab. 2018;19(3):170-191. doi: 10.2174/1389200218666170912161449. Curr Drug Metab. 2018. PMID: 28901254 Free PMC article. Review.
-
The use of supplementary immunisation activities to improve uptake of current and future vaccines in low-income and middle-income countries: a systematic review protocol.BMJ Open. 2014 Feb 18;4(2):e004429. doi: 10.1136/bmjopen-2013-004429. BMJ Open. 2014. PMID: 24549166 Free PMC article.
-
Rotavirus G and P types circulating in the eastern region of Kenya: predominance of G9 and emergence of G12 genotypes.Pediatr Infect Dis J. 2014 Jan;33 Suppl 1(Suppl 1):S85-8. doi: 10.1097/INF.0000000000000059. Pediatr Infect Dis J. 2014. PMID: 24343620 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
